Stay updated on Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Sign up to get notified when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    - Version history updated: Revision v3.5.0 added; Revision v3.4.3 removed.
    Difference
    0.1%
    Check dated 2026-03-21T00:52:23.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Version bump from v3.4.2 to v3.4.3; study details and user-facing content remain the same.
    Difference
    0.1%
    Check dated 2026-03-06T18:16:21.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    Added 'Gastric cancer' as a keyword and included the Genetic and Rare Diseases Information Center under Resources. Page revision updated from v3.4.1 to v3.4.2.
    Difference
    0.2%
    Check dated 2026-02-13T12:35:09.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    A minor page revision tag was added: Revision: v3.4.1, updating from v3.4.0, with no changes to study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T23:40:55.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Revision tag updated from v3.3.3 to v3.3.4. No substantive changes to the study details page are evident.
    Difference
    0.1%
    Check dated 2026-01-15T03:53:52.000Z thumbnail image
  8. Check
    92 days ago
    Change Detected
    Summary
    Added a Locations section listing Massachusetts, New York, and Pennsylvania as study sites; standalone entries for Massachusetts Locations, New York Locations, and Pennsylvania Locations were removed. Updated the page to revision v3.3.3 and removed the HHS Vulnerability Disclosure link.
    Difference
    0.4%
    Check dated 2025-12-24T13:51:46.000Z thumbnail image

Stay in the know with updates to Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telomelysin+Pembrolizumab in Esophagogastric Adenocarcinoma Clinical Trial page.